| Literature DB >> 35160103 |
Keiko Iwai1, Emi Ushigome1, Kazufumi Okada2, Isao Yokota2, Saori Majima1, Naoko Nakanishi1, Yoshitaka Hashimoto1, Hiroshi Okada3, Takafumi Senmaru1, Masahide Hamaguchi1, Mai Asano1, Masahiro Yamazaki1, Michiaki Fukui1.
Abstract
Hypertension usually coexists with diabetes mellitus and significantly increases the risk of macrovascular complications. Blood pressure measured at home, especially nocturnal blood pressure, is particularly important because it is more strongly associated with target organ damage than clinical blood pressure measurements. Regular moderate aerobic exercise has been shown to have anti-hypertensive effects. This study aimed to investigate the effects of aerobic exercise on home blood pressure in patients with diabetes. This randomized crossover trial was based on outpatient treatment at a university hospital. In this randomized crossover trial, 124 patients with type 2 diabetes were randomly assigned to two groups over 56 days: an exercise preceding group (exercise intervention for 28 days and then no exercise intervention for the following 28 days) and an exercise lagging group (no exercise intervention for 28 days and then exercise intervention for the following 28 days). The associations between the nocturnal blood pressure and exercise intervention were assessed accordingly. A decrease in blood pressure was observed in the morning and evening, at 2 a.m. and 3 a.m. after exercise intervention; however, there was no significant difference between groups. Moderate exercise was not effective in lowering nocturnal blood pressure in this study.Entities:
Keywords: aerobic exercise; home blood pressure; hypertension; randomized crossover trial; type 2 diabetes
Year: 2022 PMID: 35160103 PMCID: PMC8836688 DOI: 10.3390/jcm11030650
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Overview of assessment schedule and measures.
| Study Follow-Up Visits | ||||
|---|---|---|---|---|
| TIMEPOINT | Enrolment | Allocation | 1 Month | 2 Months |
| ENROLMENT: | ||||
| Eligibility screen | X | |||
| Informed consent | X | |||
| Allocation | X | |||
| Exercise preceding group | X | |||
| Exercise lagging group | X | |||
| HBP measurement | X | X | ||
| ASSESSMENTS: | ||||
| Demographics | X | |||
| InBody | X | X | X | |
| Sleeping habits | X | X | X | |
| Medication review | X | X | X | |
| Body weight | X | X | X | |
| Hemoglobin A1c | X | X | X | |
| Blood glucose | X | X | X | |
| Serum lipid profile | X | X | X | |
| Renal function | X | X | X | |
| Liver function | X | X | X | |
| Urinary albumin excretion | X | X | X | |
HBP: home blood pressure.
Figure 1Flow diagram of the study.
Clinical characteristics of patients.
| Variables | Preceding | Lagging | Overall |
|---|---|---|---|
| Men | 33 (61.1) | 23 (53.5) | 56 (57.7) |
| Women | 21 (38.9) | 20 (46.5) | 41 (42.3) |
| Age (years) | 69 (63–74) | 69 (61–72) | 69 (62.8–74) |
| Duration of diabetes mellitus (years) | 9.5 (5–16) | 14 (7–20) | 12 (5.8–17) |
| Body mass index (kg/m2) | 24.6 (22.4–26.8) | 23.3 (21.6–26.3) | 24.3 (22.0–26.6) |
| Hemoglobin A1c (%) | 7.0 (6.5–7.8) | 7.2 (6.7–7.8) | 7.2 (6.6–7.8) |
| LDL cholesterol (mg/dL) | 101.5 (87.5–121.3) | 109.0 (86–122) | 104.0 (87.5–122) |
| HDL cholesterol (mg/dL) | 55.5 (46.8–69.0) | 58.0 (50–68) | 57.5 (48–68.3) |
| Triglycerides (mg/dL) | 123.5 (93.0–207.8) | 117 (88–159)) | 122.5 (92.5–181.8) |
| eGFR (mL/min/1.73 m2) | 65.7 (57.7–82.1) | 66.1 (55.5–77.1) | 66.1 (57–77.3) |
| Smoking status | |||
| current | 6 (11.1) | 2 (4.7) | 8 (8.2) |
| past | 18 (33.3) | 15 (34.9) | 33 (34.0) |
| never | 30 (55.6) | 26 (60.5) | 56 (57.7) |
| Alcohol consumption status | |||
| everyday | 10 (18.5) | 4 (9.3) | 14 (14.4) |
| social | 15 (27.8) | 14 (32.6) | 29 (29.9) |
| none | 29 (53.7) | 25 (58.1) | 54 (55.7) |
| Diabetes complication | |||
| Nephropathy (microalbuminuria) | 18 (33.3) | 15 (34.9) | 33 (34.0) |
| Retinopathy | 10 (18.5) | 13 (30.2) | 23 (23.7) |
| Neuropathy | 14 (25.9) | 8 (18.6) | 22 (22.7) |
| Macrovascular complication | 2 (3.8) | 5 (11.6) | 7 (7.2) |
| Use of antihypertensive medication | 32 (59.3) | 23 (53.5) | 55 (57.0) |
| Use of SGLT-2 inhibitor | 20 (37.0) | 17 (40.5) | 37 (38.0) |
LDL: low-density lipoprotein; HDL: high-density lipoprotein; eGFR: estimated glomerular filtration rate; SGLT-2: sodium-glucose transporter-2. For categorical variables, n (%) was calculated. Continuous variables are presented as median (interquartile range).
Sensitivity analysis: Confirmation that there is no carry-over effect (primary endpoint).
| Period 1 | Period 2 | EX Period–Non-EX Period | |
|---|---|---|---|
| Preceding group | 118.6 (114.4–122.8) | 119.2 (115.3–123.1) | −0.6 (−3.6–2.5) |
| Lagging group | 116.6 (113.0–120.2) | 115.6 (111.8–119.4) | −1.0 (−3.0–0.9) |
| 0.8149 |
EX: exercise; * Student’s t-test p-value for “exercise-non-exercise”, comparison between groups.
Comparison of primary endpoint and secondary endpoints analysis before and after exercise intervention (mean [95% CI]).
| Variables |
| EX Period | Non-EX Period | EX Period-Non-EX Period | |
|---|---|---|---|---|---|
| Mean SBP at 2 a.m. | 97 | 117.3 (114.4–120.1) | 118.1 (115.4–120.1) | −0.8 (−2.7–1.1) | 0.21 |
| Mean SBP at 3 a.m. | 97 | 116.9 (114.2–119.5) | 117.4 (114.7–120.0) | −0.5 (−2.3–1.3) | 0.30 |
| Mean SBP at 4 a.m. | 97 | 119.3 (116.5–122.1) | 117.9 (114.9–120.8) | 1.4 (−0.3–3.2) | 0.95 |
| Mean morning SBP | 87 | 130.1 (126.9–133.2) | 130.2 (127.1–133.3) | −0.1 (−2.0–1.7) | 0.44 |
| Mean evening SBP | 94 | 125.7 (122.3–129.1) | 126.7 (123.4–130.0) | −1.0 (−2.8–0.9) | 0.15 |
| BP variation at 2 a.m. | 97 | 10.26 (9.25–11.28) | 10.28 (9.31–11.26) | −0.02 (−1.37–1.32) | 0.49 |
| BP variation at 3 a.m. | 97 | 9.89 (8.80–10.99) | 10.59 (9.48–11.71) | −0.70 (−2.15–0.75) | 0.17 |
| BP variation at 4 a.m. | 97 | 9.50 (8.41–10.58) | 9.67 (8.51–10.83) | −0.17 (−1.50–116) | 0.40 |
| BP variation at morning | 87 | 3.53 (2.99–4.06) | 3.59 (3.07–4.12) | −0.07 (−0.64–0.50) | 0.40 |
| BP variation at evening | 94 | 3.46 (2.97–3.96) | 3.57 (3.09–4.05) | −0.10 (−0.55–0.34) | 0.32 |
| Hemoglobin A1c | 97 | 7.18 (7.02–7.34) | 7.24 (7.07–7.41) | −0.66 (−0.12–0.00) | 0.03 |
| Blood glucose | 97 | 145.6 (138.1–153.1) | 153.2 (143.2–163.1) | −7.6 (−17.5–2.4) | 0.07 |
| LDL | 97 | 107.4 (101.7–113.1) | 109.4 (103.5–115.4) | −2.0 (−5.5–1.5) | 0.12 |
| Triglycerides | 97 | 149.2 (129.9–168.6) | 147.5 (128.8–166.2) | 1.7 (−15.1–18.6) | 0.58 |
| Creatinine | 96 | 0.82 (0.77–0.87) | 0.82 (0.77–0.87) | 0.00 (−0.01–0.02) | 0.74 |
| AST | 97 | 27.2 (23.9–30.6) | 25.2 (21.9–28.5) | 2.0 (0.3–3.8) | 0.99 |
| ALT | 97 | 27.3 (22.6–32.0) | 27.7 (23.0–32.4) | −0.4 (−2.1–1.3) | 0.32 |
| Urinary albumin excretion | 81 | 102.0 (46.3–157.8) | 125.7 (23.3–228.1) | −23.7 (−89.7–42.3) | 0.24 |
| Body weight | 97 | 64.8 (62.0–67.5) | 65.0 (62.2–67.7) | −0.2 (−0.4–0.0) | 0.02 |
| Body mass index | 97 | 24.5 (23.7–25.3) | 24.5 (23.7–25.4) | 0.0 (−0.1–0.0) | 0.16 |
| SMI | 97 | 6.95 (6.69–7.22) | 7.08 (6.81–7.35) | −0.13 (−0.35–0.10) | 0.13 |
EX: exercise; SBP: systolic blood pressure; LDL: low-density lipoprotein cholesterol; AST: aspartate aminotransferase; ALT: alanine aminotransferase; SMI: skeletal muscle index; CI: confidence interval. Continuous variables are presented as median (interquartile range).
Figure 2SBP at the non-EX period and the EX period (A) morning SBP (mmHg); (B) evening SBP (mmHg); (C) nocturnal SBP (mmHg) at 2:00 a.m.; (D) nocturnal SBP (mmHg) at 3:00 a.m.; (E) nocturnal SBP (mmHg) at 4:00 a.m.
The number of each nocturnal SBP pattern at the non-EX period and at the EX period and the ratio of people with reduced and improved the nocturnal BP.
| EX Period BP Pattern (Number) | Percentage of People | Percentage of People | ||||
|---|---|---|---|---|---|---|
| Non-EX Period | Non-Dipper | Dipper | Extreme Dipper | Riser | ||
| Non-dipper | 14 | 8 | 0 | 2 | 33.3 | 33.3 |
| Dipper | 9 | 26 | 4 | 2 | 9.8 | N/A |
| Extreme dipper | 1 | 6 | 12 | 0 | 0 | 33.3 |
| Riser | 6 | 1 | 0 | 6 | 50 | 7.1 |
EX: exercise, N/A: not applicable.